AU2006227833A1 - Compounds having activity in correcting mutant-CFTR processing and uses thereof - Google Patents
Compounds having activity in correcting mutant-CFTR processing and uses thereof Download PDFInfo
- Publication number
- AU2006227833A1 AU2006227833A1 AU2006227833A AU2006227833A AU2006227833A1 AU 2006227833 A1 AU2006227833 A1 AU 2006227833A1 AU 2006227833 A AU2006227833 A AU 2006227833A AU 2006227833 A AU2006227833 A AU 2006227833A AU 2006227833 A1 AU2006227833 A1 AU 2006227833A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- cftr
- pharmaceutical composition
- pharmaceutically acceptable
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66350105P | 2005-03-18 | 2005-03-18 | |
US60/663,501 | 2005-03-18 | ||
PCT/US2006/008267 WO2006101740A2 (en) | 2005-03-18 | 2006-03-08 | Compounds having activity in correcting mutant-cftr processing and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2006227833A1 true AU2006227833A1 (en) | 2006-09-28 |
Family
ID=37024308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006227833A Abandoned AU2006227833A1 (en) | 2005-03-18 | 2006-03-08 | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
Country Status (12)
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US7495103B2 (en) | 2004-06-24 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
EP1974212A1 (en) * | 2005-12-27 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
PT1993360T (pt) | 2005-12-28 | 2017-05-25 | Vertex Pharma | Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
DK2674428T3 (en) | 2006-04-07 | 2016-04-18 | Vertex Pharma | Modulators of ATP binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
JP2010523579A (ja) | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | Cftr阻害剤化合物およびそれらの使用 |
MX2009012077A (es) | 2007-05-07 | 2009-11-19 | Novartis Ag | Compuestos organicos. |
US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
AU2008310097B2 (en) | 2007-10-09 | 2013-05-16 | Merck Patent Gmbh | Pyridine derivatives useful as glucokinase activators |
US8389736B2 (en) * | 2007-10-16 | 2013-03-05 | The Regents Of The University Of California | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
PL2578571T3 (pl) | 2007-11-16 | 2016-03-31 | Vertex Pharma | Modulatory izochinolinowe transporterów zawierających kasetę wiążącą ATP |
MX367154B (es) | 2007-12-07 | 2019-08-07 | Vertex Pharma | Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico. |
KR101578235B1 (ko) | 2007-12-10 | 2015-12-16 | 노파르티스 아게 | 유기 화합물 |
ES2552990T3 (es) | 2008-03-31 | 2015-12-03 | Vertex Pharmaceuticals Incorporated | Derivados de piridilo como moduladores del CFTR |
US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
WO2009131952A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising thiazole derivatives |
WO2009131957A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009150137A2 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
US20120058918A1 (en) * | 2009-02-02 | 2012-03-08 | Chromocell Corporation | Cell lines expressing cftr and methods of using them |
NZ624460A (en) | 2009-03-20 | 2015-12-24 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
ES2951520T3 (es) | 2010-03-25 | 2023-10-23 | Vertex Pharma | Síntesis e intermedios de (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1H-indol-5il)-ciclopropanocarboxamida |
HUE029611T2 (en) | 2010-04-07 | 2017-03-28 | Vertex Pharma | 3- (6- (1- (2,2-Difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid |
CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
WO2012027247A2 (en) | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
US20130303761A1 (en) | 2010-09-14 | 2013-11-14 | Instytut Biochemii I Biofizyki Pan | Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
CA2754237A1 (en) | 2011-05-27 | 2012-11-27 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
WO2012166654A1 (en) * | 2011-05-27 | 2012-12-06 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
US8798939B2 (en) | 2011-06-29 | 2014-08-05 | Janssen Pharmaceutica N.V. | Methods for designing, selecting and/or optimizing allosteric processing inhibitors for matrix metalloproteinases |
US8753857B2 (en) | 2011-06-29 | 2014-06-17 | Janssen Pharmaceutica N.V. | Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor |
WO2013003360A1 (en) * | 2011-06-29 | 2013-01-03 | Janssen Pharmaceutica Nv | Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases |
ES2622154T3 (es) | 2011-11-08 | 2017-07-05 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores de cassete de unión atp-binding |
KR20140117612A (ko) | 2012-01-25 | 2014-10-07 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-다이플루오로벤조[d][1,3]다이옥솔-5-일) 사이클로프로판카르복사미도)-3-메틸피리딘-2-일)벤조산의 제형 |
MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
JP6302923B2 (ja) | 2012-11-02 | 2018-03-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftrが媒介する疾患の処置のための医薬組成物 |
ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
GB201405991D0 (en) * | 2014-04-03 | 2014-05-21 | Cambridge Entpr Ltd | Novel compounds |
PL3424534T3 (pl) | 2014-04-15 | 2021-11-22 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
CN112279808B (zh) | 2014-10-06 | 2024-03-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
CA2969587A1 (en) | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
US10828288B2 (en) | 2015-01-27 | 2020-11-10 | Rutgers, The State University Of New Jersey | Hydrazone derivatives for the treatment of cancer |
WO2016123246A1 (en) | 2015-01-27 | 2016-08-04 | Rutgers, The State University Of New Jersey | (thio, oxo and seleno) semicarbazone complexes with zinc and their use for treating cancer |
WO2016123250A1 (en) | 2015-01-27 | 2016-08-04 | Rutgers, The State University Of New Jersey | Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer |
US10604480B2 (en) | 2015-01-27 | 2020-03-31 | Rutgers, The State University Of New Jersey | (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer |
ITUB20153714A1 (it) * | 2015-09-18 | 2017-03-18 | Luigina Romani | Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica. |
WO2016129005A1 (en) * | 2015-02-09 | 2016-08-18 | Luigina Romani | Thymosin alpha 1 for use in treatment of cystic fibrosis |
EP3359144A1 (en) * | 2015-10-09 | 2018-08-15 | AbbVie S.À.R.L. | Potentiator-corrector combinations useful in the treatment of cystic fibrosis |
JP7270641B2 (ja) | 2018-01-11 | 2023-05-10 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | サルコグリカン異常症の併用治療 |
EP3846801A1 (en) | 2018-09-09 | 2021-07-14 | Qanatpharma AG | Use of cftr modulators for treating cerebrovascular conditions |
KR102399037B1 (ko) * | 2020-01-06 | 2022-05-17 | 성균관대학교산학협력단 | 아민화된 아진의 신규한 제조방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0069154B1 (en) * | 1981-01-13 | 1986-10-15 | Mitsui Toatsu Kagaku Kabushiki Kaisha | Novel thiazole compounds, process for their preparation, and medicinal composition containing same |
JPS649935A (en) * | 1987-06-30 | 1989-01-13 | Kyowa Hakko Kogyo Kk | Remedy for hepatopathy |
AU2000092A (en) | 1991-06-21 | 1993-01-25 | Boehringer Mannheim Italia S.P.A. | 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract |
US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
EP1353676A4 (en) * | 2000-12-29 | 2006-05-31 | Alteon Inc | METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS |
HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
SE0201837D0 (sv) * | 2002-06-14 | 2002-06-14 | Astrazeneca Ab | Chemical compounds |
US7329682B2 (en) * | 2003-04-03 | 2008-02-12 | Ewha University-Industry Collaboration Foundation | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative |
WO2004098510A2 (en) * | 2003-04-30 | 2004-11-18 | Beth Israel Deaconess Medical Center | Cystic fibrosis therapy |
WO2004110352A2 (en) * | 2003-05-16 | 2004-12-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
-
2006
- 2006-03-08 MX MX2007011512A patent/MX2007011512A/es not_active Application Discontinuation
- 2006-03-08 RU RU2007138584/04A patent/RU2007138584A/ru not_active Application Discontinuation
- 2006-03-08 BR BRPI0608453-2A patent/BRPI0608453A2/pt not_active Application Discontinuation
- 2006-03-08 KR KR1020077024001A patent/KR20070114820A/ko not_active Application Discontinuation
- 2006-03-08 WO PCT/US2006/008267 patent/WO2006101740A2/en active Application Filing
- 2006-03-08 JP JP2008501913A patent/JP2008538107A/ja not_active Withdrawn
- 2006-03-08 AU AU2006227833A patent/AU2006227833A1/en not_active Abandoned
- 2006-03-08 CN CNA2006800150356A patent/CN101605543A/zh active Pending
- 2006-03-08 CA CA002600869A patent/CA2600869A1/en not_active Abandoned
- 2006-03-08 US US11/908,591 patent/US8143295B2/en active Active
- 2006-03-08 EP EP06737438A patent/EP1863522A4/en not_active Withdrawn
-
2007
- 2007-09-17 IL IL185999A patent/IL185999A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006101740A3 (en) | 2009-06-04 |
US8143295B2 (en) | 2012-03-27 |
EP1863522A4 (en) | 2010-11-10 |
IL185999A0 (en) | 2008-08-07 |
BRPI0608453A2 (pt) | 2009-12-29 |
US20080318984A1 (en) | 2008-12-25 |
KR20070114820A (ko) | 2007-12-04 |
EP1863522A2 (en) | 2007-12-12 |
JP2008538107A (ja) | 2008-10-09 |
WO2006101740A2 (en) | 2006-09-28 |
RU2007138584A (ru) | 2009-04-27 |
MX2007011512A (es) | 2007-12-07 |
CA2600869A1 (en) | 2006-09-28 |
CN101605543A (zh) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8143295B2 (en) | Compounds having activity in correcting mutant-CFTR processing and uses thereof | |
US7696244B2 (en) | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof | |
US7939558B2 (en) | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof | |
EP1085848B1 (en) | Inhibitors of transcription factor nf-kappa b | |
US8389736B2 (en) | Compounds having activity in correcting mutant-CFTR processing and uses thereof | |
RU2688191C2 (ru) | Новое лечение | |
US7087608B2 (en) | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
CA2736441A1 (en) | Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors | |
US20040235800A1 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
WO2009051910A1 (en) | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof | |
US20040063695A1 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
AU4699699A (en) | Inhibitors of transcription factor NF-KappaB | |
CA2882881A1 (en) | Therapeutic agent for systemic bone disease and use thereof | |
US9073863B2 (en) | Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof | |
JP7061310B2 (ja) | 慢性脂肪性疾患の予防および治療用医薬 | |
US20130095059A1 (en) | Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model | |
EA038527B1 (ru) | Способ лечения респираторного заболевания или состояния, композиции и наборы, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид | |
MXPA00012498A (en) | INHIBITORS OF TRANSCRIPTION FACTOR NF-&kgr;B |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |